Vertex Pharmaceuticals VRTX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Vertex Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Vertex Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vertex Pharmaceuticals's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vertex Pharmaceuticals's financing cash flow?
- Vertex Pharmaceuticals (VRTX) reported financing cash flow of -$538.8M in Q1 2026.
- How has Vertex Pharmaceuticals's financing cash flow changed year-over-year?
- Vertex Pharmaceuticals's financing cash flow increased by 20.8% year-over-year, from -$680.4M to -$538.8M.
- What is the long-term trend for Vertex Pharmaceuticals's financing cash flow?
- Over 3 years (2021 to 2025), Vertex Pharmaceuticals's financing cash flow has grown at a 14.4% compound annual growth rate (CAGR), from -$1.51B to -$2.26B.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.